Press coverage about Capricor Therapeutics (NASDAQ:CAPR) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capricor Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 48.506078861164 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern’s rankings:
Several analysts have recently issued reports on CAPR shares. HC Wainwright reiterated a “buy” rating and issued a $8.60 target price (up from $6.50) on shares of Capricor Therapeutics in a research note on Friday, January 26th. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Tuesday, February 13th.
CAPR stock opened at $1.28 on Friday. Capricor Therapeutics has a 1 year low of $0.63 and a 1 year high of $4.25. The stock has a market capitalization of $37.97, a PE ratio of -2.91 and a beta of -3.29.
Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The firm had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.63 million. analysts expect that Capricor Therapeutics will post -0.42 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Capricor Therapeutics (NASDAQ:CAPR) Stock Price” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-capricor-therapeutics-capr-stock-price.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.